Terumo (TSE:4543) ROCE % : 6.29% (As of Mar. 2025)

View and export this data going back to 1982. Start your Free Trial

What is Terumo ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Terumo's annualized ROCE % for the quarter that ended in Mar. 2025 was 6.29%.

Terumo ROCE % Historical Data

The historical data trend for Terumo's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Terumo ROCE % Chart

Terumo Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

ROCE %

Get a 7-Day Free Trial

9.16

9.64

8.97

10.13

10.58

Terumo Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															10.19	12.73	11.34	11.82	6.29

Terumo ROCE % Calculation

Terumo's annualized ROCE % for the fiscal year that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2025 )		(A: Mar. 2024 )		(A: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2025 )		(A: Mar. 2024 )		(A: Mar. 2025 )
	=	160821	/	( ( (1831402 - 379152)	+	(1828393 - 240965) )	/ 2 )
	=	160821	/	( (1452250	+	1587428)	/ 2 )
	=	160821	/	1519839
	=	10.58 %

Terumo's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	100676	/	( ( (1877627 - 263847)	+	(1828393 - 240965) )	/ 2 )
	=	100676	/	( ( 1613780	+	1587428 )	/ 2 )
	=	100676	/	1600604
	=	6.29 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

Terumo (TSE:4543) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Terumo ROCE % Related Terms

Thank you for viewing the detailed overview of Terumo's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Terumo Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Terumo Corp (TSE:4543) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TRUMY:USA TRUMF:USA TUO:Germany

Address

2-44-1 Hatagaya, Shibuya-ku, Tokyo, JPN, 151-0072

Website

https://www.terumo.com

Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2025, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 38% of Terumo's revenue.

Terumo Headlines

No Headlines